𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer

✍ Scribed by Ming Zhao; Yohei Tominaga; Kenoki Ohuchida; Kazuhiro Mizumoto; Lin Cui; Shingo Kozono; Hayato Fujita; Ryo Maeyama; Hiroki Toma; Masao Tanaka

Book ID
108589191
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
787 KB
Volume
103
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined gemcitabine and radioimmunother
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 116 KB πŸ‘ 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

Gemcitabine in combination with 5-fluoro
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
✍ Helmut Oettle; Hanno Riess πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 102 KB πŸ‘ 1 views

Pancreatic cancer is one of the most frequently reported gastrointestinal tumors and has been reported to have a 5-year survival rate of < 5%. It is most commonly diagnosed at an advanced stage and until recently, the most frequently administered treatment for patients with advanced disease has been